OTC Bulletin Board

S & P Company Insight for NANOVIRICIDES INC
 
 Profile

 
Business Summary: NanoViricides, Inc., a development stage nano-biopharmaceutical company, engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States.
 
Address
  135 Wood St., Suite 205
  West Haven , CT 06516
  Phone: 203-937-6137
  Website: http://www.nanoviricides.com
Auditor
  Holtz Rubenstein Reminick
  New York
Transfer Agent
  Empire Stock Transfer Inc.
Employees:  4
ShareHolders:  210
Founded:  2000
Domicile:  Nevada
 
  
 
 Background

 
NanoViricides, Inc., a development stage nano-biopharmaceutical company, engages in the discovery, development, and commercialization of anti-viral therapeutics primarily in the United States. It has licenses in perpetuity to develop drugs for the treatment of human viral diseases, such as human immunodeficiency virus, Hepatitis B Virus, Hepatitis C Virus (HCV), Herpes Simplex Virus, Rabies, Influenza, and Asian Bird Flu Virus. The company's products under development include FluCide-I for the treatment of common influenzas and avian influenza H5N1; AviFluCide-I against H5N1, the avian influenza strain; FluCide-HP against highly pathogenic avian influenza viruses; RabiCide-I, a nanoviricide against rabies; and HCV, a Hepatitis C nanoviricide. It also provides HivCide-I, a drug project against HIV-I; HivCide-II, a targeted nanoviricide against HIV strains; and EKCCide-I, a nanoviricide drug, which indicates efficacy and safety of a drug candidate against the severe pink eye disease caused by adenoviruses called epidemic kerato-conjunctivitis. NanoViricides, Inc. has a pre-clinical study agreement with Thevac, LLC for the evaluation of the company's universal anti-influenza drug candidate FluCide; and has a research agreement with the University of California-San Francisco for testing of its anti-HIV drug candidates. The company was founded in 2005 and is headquartered in West Haven, Connecticut.
History:  INCORPORATED in Nevada Apr. 1, 2005 as Edot-com.com, Inc., and on Apr. 15, 2005, merged a Colorado company of the same name incorporated on July 25, 2000. Name changed to NanoViricides, Inc. June 28, 2005. June 1, 2005, issued 80,000,000 Common shares to acquire NanoViricides, Inc., a privately owned Forida concern (incorporated on May 12, 2005).
 
 
 
 
  
 
 Management

 

Management
OfficersPosition
 Anil  DiwanChairman & President
 Eugene  SeymourChief Executive Officer & Acting Chief Financial Officer

Directors
 Anil  Diwan
 Eugene  Seymour
 
  
 
 Annual Report

 
Annual Report
 
Income Statement
  20092008
Research and development, net1,7341,564
General and administrative 1,0861,228
Interest income3254
Net income(2,788)(2,738)
Share earns. basic($0.02)($0.02)
Share earns. diluted($0.02)($0.02)
 
Balance Sheet
  20092008
Assets:
Cash & equiv.1,689816
Other curr. assets109103
Prepayments322329
Tot. curr assets2,1201,248
Net property689134
Security deposit--80
Trademark1927
Total assets3,0011,468
Liabilities:
Accts. pay.448670
Accruals68355
Tot. curr. liabs.5161,025
Com. stk. p.$0.001125119
Paid-in cap.14,4569,532
Stock subscription receivable (100)--
Retained earns.(11,996)(9,208)
Total liabs.3,0011,468
 
 * Effective June 1, 2005, Edot-com.com, Inc. (ECMM) issued 80,000,000 com. shs. for all of the outstanding shs. of Nanoviricide, Inc. (NVI). Transaction was acctd. for as a reverse acquis., with NVI being deemed the acquiring company. On June 28, 2005, NVI was merged into its parent ECMM and the separate corporate existence of NVI ceased. Effective on the same date, Edot-com.com, Inc. changed its name to NanoViricides, Inc.
 
  
 
 Interim Report

 
Interim Report   
 
Data Not Available
 
 
 
 
  
 
 Pro Forma Report

 
Pro Forma Report   
 
Data Not Available
 
 
 
 
  
 
 Quarterly Report

 
Quarterly Report Information   
 
Quarterly Revenue, US$
YearQuarterRevenue
  2009   1Nil
  2009   2Nil
  2009   3Nil
  2009   Full Year Nil
  2008   1Nil
  2008   2Nil
  2008   3Nil
  2008   4Nil
  2008   Full Year Nil
  2007   2Nil
  2007   3Nil
  2007   Full Year Nil
  2006   Full Year Nil
 
 
Quarterly Net Income, US$
YearQuarterRevenue
  2010   1(730,000)
  2010   2(930,000)
  2010   3(2,420,000)
  2009   1(740,000)
  2009   2(630,000)
  2009   3(790,000)
  2009   4(620,000)
  2009   Full Year (2,790,000)
  2008   1(570,000)
  2008   2(380,000)
  2008   3(790,000)
  2008   4(990,000)
  2008   Full Year (2,740,000)
  2007   2(690,000)
  2007   3(920,000)
  2007   Full Year (3,120,000)
  2006   Full Year (3,230,000)
  2005   Full Year (430,000)
 
 
Quarterly EPS, US$
YearQuarterRevenue
  2010   1(.01)
  2010   2(.01)
  2010   3(.02)
  2009   1(.01)
  2009   2Nil
  2009   3(.01)
  2009   4(.01)
  2009   Full Year (.02)
  2008   1(.01)
  2008   2Nil
  2008   3(.01)
  2008   4(.01)
  2008   Full Year (.02)
  2007   1(.01)
  2007   2(.01)
  2007   3(.01)
  2007   4(.01)
  2007   Full Year (.03)
  2006   1Nil
  2006   2(.01)
  2006   3(.01)
  2006   4(.01)
  2006   Full Year (.03)
 
  
 
 Stock Data

 
 
Capitalization as of 06/30/2009:
 
 Authorized SharesOutstanding Shares
Common $0.001 par300,000,000125,299,457
 
LONG TERM DEBT: None.
 
Common $0.001 par
 
Stockholders:  06/30/2009, 210.
PRINCIPAL STOCKHOLDERS: June 30, 2009, TheraCour Pharma, Inc. owned or controlled 27.3% of the Common, Anil Diwan 8.8% and Eugene Seymour 6.8%.
 
Transfer Agent:  Empire Stock Transfer Inc.   Henderson , NV
 
OTC Bulletin Board( Primary): NNVC
 
ExchangeYearHighLow
OTC Bulletin Board20091.29000.4100
OTC Bulletin Board20081.78000.3500
OTC Bulletin Board20071.46000.3300
Over The Counter20063.75000.6000
Over The Counter20051.27000.0320
 
DIVIDENDS: Common $0.001 par: No cash. Common split 3.2-for-1, May 12, 2005.